Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Patient preferences for treatment: report from a randomised comparison of treatment strategies in early rheumatoid arthritis (BeSt trial).
Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, Kerstens PJ, Grillet BA, de Jager MH, Han KH, Speyer I, van der Lubbe PA, Seys PE, Breedveld FC, Dijkmans BA. Goekoop-Ruiterman YP, et al. Among authors: de jager mh, de vries bouwstra jk. Ann Rheum Dis. 2007 Sep;66(9):1227-32. doi: 10.1136/ard.2006.068296. Epub 2007 Apr 3. Ann Rheum Dis. 2007. PMID: 17405834 Free PMC article. Clinical Trial.
Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial.
de Jong PH, Hazes JM, Barendregt PJ, Huisman M, van Zeben D, van der Lubbe PA, Gerards AH, de Jager MH, de Sonnaville PB, Grillet BA, Luime JJ, Weel AE. de Jong PH, et al. Among authors: de jager mh, de sonnaville pb. Ann Rheum Dis. 2013 Jan;72(1):72-8. doi: 10.1136/annrheumdis-2011-201162. Epub 2012 Jun 7. Ann Rheum Dis. 2013. PMID: 22679301 Clinical Trial.
Best cost-effectiveness and worker productivity with initial triple DMARD therapy compared with methotrexate monotherapy in early rheumatoid arthritis: cost-utility analysis of the tREACH trial.
de Jong PH, Hazes JM, Buisman LR, Barendregt PJ, van Zeben D, van der Lubbe PA, Gerards AH, de Jager MH, de Sonnaville PB, Grillet BA, Luime JJ, Weel AE. de Jong PH, et al. Among authors: de jager mh, de sonnaville pb. Rheumatology (Oxford). 2016 Dec;55(12):2138-2147. doi: 10.1093/rheumatology/kew321. Epub 2016 Aug 30. Rheumatology (Oxford). 2016. PMID: 27581208 Clinical Trial.
Treatment decisions and related costs differ significantly depending on the choice of a disease activity index in RA, according to 1987 and 2010 classification criteria.
de Jong PH, Hazes JM, van Zeben D, van der Lubbe PA, de Jager MH, de Sonnaville PB, Luime JJ, Weel AE. de Jong PH, et al. Among authors: de jager mh, de sonnaville pb. Rheumatology (Oxford). 2012 Jul;51(7):1269-77. doi: 10.1093/rheumatology/kes008. Epub 2012 Feb 29. Rheumatology (Oxford). 2012. PMID: 22378716 Clinical Trial.
Two-year cost effectiveness between two gradual tapering strategies in rheumatoid arthritis: cost-utility analysis of the TARA trial.
van Mulligen E, Weel AE, Kuijper TM, Denissen NHAM, Gerards AH, de Jager MH, Lam-Tse WK, Hazes JM, van der Helm-van Mil A, de Jong PHP, Luime JJ. van Mulligen E, et al. Among authors: de jager mh. Ann Rheum Dis. 2020 Dec;79(12):1550-1556. doi: 10.1136/annrheumdis-2020-217528. Epub 2020 Sep 9. Ann Rheum Dis. 2020. PMID: 32907801 Free PMC article. Clinical Trial.
Limited value for ultrasonography in predicting flare in rheumatoid arthritis patients with low disease activity stopping TNF inhibitors.
Lamers-Karnebeek FB, Luime JJ, Ten Cate DF, Teerenstra S, Swen NWAA, Gerards AH, Hendrikx J, van Rooyen EM, Voorneman R, Haagsma C, Basoski N, de Jager M, Ghiti Moghadam M, Efde MN, Goekoop-Ruiterman YPM, van Riel PLCM, Jacobs JWG, Jansen TL. Lamers-Karnebeek FB, et al. Rheumatology (Oxford). 2017 Sep 1;56(9):1560-1565. doi: 10.1093/rheumatology/kex184. Rheumatology (Oxford). 2017. PMID: 28595367 Clinical Trial.
35 results